GLP-1 / Weight Loss

Wegovy vs Mounjaro: The Two Leading Weight Loss Drugs Compared

Verdict Summary

Both are highly effective. Mounjaro produces greater average weight loss (~20-22% vs ~15%) but Wegovy has longer obesity-specific approval history. The choice often comes down to insurance and individual response.

Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →

At a Glance

DimensionWegovyMounjaro
Active CompoundSemaglutide 2.4mgTirzepatide
MechanismGLP-1 agonistGIP + GLP-1 dual agonist
Avg. Weight Loss~15%~20-22%
FDA Obesity Approval20212023 (Zepbound)
DosingOnce weeklyOnce weekly

Wegovy Deep Dive

Wegovy is the obesity-specific formulation of semaglutide at 2.4mg weekly. The STEP trials established it as a landmark obesity treatment with ~15% average weight loss and significant cardiometabolic benefits.

Mounjaro Deep Dive

Mounjaro's obesity indication (Zepbound) was approved in 2023 after SURMOUNT trials showed ~20-22% weight loss. Its dual GIP/GLP-1 mechanism may explain superior efficacy vs GLP-1 monotherapy.

How to Choose

Choose Wegovy if…

  • Wegovy has better insurance coverage for you
  • You prefer the longer obesity-specific track record
  • You are sensitive to GIP receptor effects

Choose Mounjaro if…

  • Maximum weight loss is the priority
  • You have not achieved adequate results on semaglutide
  • Zepbound is covered by your insurance

Consider Both If…

Both are excellent first-line options. Many clinicians start with Wegovy and escalate to Mounjaro if response is insufficient.

Still Unsure?

Get a personalized recommendation

Take the 5-minute PeptidePilot quiz. Our algorithm evaluates your goals, body, and lifestyle to recommend the right peptide for you — vendor-neutral.

Frequently Asked Questions

More Comparisons